Enteric Coated Capsules for Oral Delivery of Anti-CD3 Monoclonal Antibody (mAb): An Early Phase Proof-of-Concept Trial

Oral delivery of monoclonal antibodies remains challenging due to their instability in the gastrointestinal tract and poor intestinal absorption. In this AAPS 2026 poster, Frontage scientists explore a promising approach using lyophilized anti-CD3 antibodies in enteric-coated capsules, demonstrating strong gastric acid resistance and pH-dependent release for targeted intestinal delivery.

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*